Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Commentary|Articles|May 12, 2026
GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
Author(s)Kyle Doherty
Fact checked by: Courtney Flaherty
We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
With the
Related to this article
Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.
Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.
Neoadjuvant PD-1–based immunotherapy plus chemotherapy produced pCRs across three cohorts in resectable locally advanced HNSCC.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
Dostarlimab monotherapy produced a 27% response rate in PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma
Early nivolumab responders sustained years-long treatment-free survival after treatment discontinuation.
Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in ovarian and endometrial cancer.
Advertisement
Advertisement